Reviewed listing: NASDAQ:NEPH · Analysis dated Oct 22, 2026
How does the company make money?
Nephros sells water filters and services for medical and commercial facilities. Hospitals and dialysis providers use the filters to reduce biological contaminants.
What supports the business?
First-half revenue rose by 20.8% to 11.23 million USD. Repeat orders and additional locations support the business.
What could improve?
More regularly supplied locations and new filter applications could increase earnings. The key is that receivables and inventory do not continue to grow faster than sales.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
3.59 USD is above the cautious model limit of 2.50 USD. The strong quarterly earnings include around 0.6 million USD in one-time tariff refunds and should not be extrapolated without adjustment.
What is the main risk?
Despite reporting a profit, nearly 1 million USD flowed out through operating activities in the half-year. Higher inventories, outstanding customer receivables, and exchange rates can weigh on available liquidity.
What is the overall assessment?
Nephros is growing through water filters and repeat orders. However, the valuation requires more sustainable cash flow than the half-year results, adjusted for the one-time tariff benefit, have shown so far.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in